“We use cookies on this website to enhance your user experience and to personalise content. By clicking any link or continuing to use our Website you agree to our cookies as per our Privacy Policy. Read More” Ok, I agree

Piperacillin Sodium And Tazobactam Sodium (Zosyn)

Trade Name : Zosyn

Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.

INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

Strength .252 g/10mLg/10mL

TAZOBACTAM SODIUM; PIPERACILLIN SODIUM beta Lactamase Inhibitors [MoA],beta Lactamase Inhibitor [EPC],Penicillin-class Antibacterial [EPC],Penicillins [CS]

Delivery Process

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

We’ll Get in Touch

Once we review your request, we’ll send you an estimated price for the medicine within 2-5 days.

Confirmation and Payment

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Product information is meant for

Wholesalers Suppliers Exporters Doctors MOH Tender Supplies Hospitals Brand CROs Comparator Supplies Generic Cooperate Sourcing Individual Patients Indian Institutional Buyers

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

GNH India is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler/ Supplier/ Exporters/ Importer from India of Piperacillin Sodium And Tazobactam Sodium (Zosyn) which is also known as Zosyn and Manufactured by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.. It is available in strength of .25; 2 g/10mL; g/10mL per ml. Read more

Piperacillin Sodium And Tazobactam Sodium (Zosyn) is supplied for Tenders/ Emergency imports/ Un - licensed, Specials, Orphan drug/ Name patient line/ RLD supplies/ Reference listed drugs/ Comparator Drug/ Bio-Similar/ Innovator samples For Clinical trials.  Click to know price.     Read less

Packaging and Delivery

Validated Cold Chain Shipment

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Inquire directly from our website and get 5% off on any medicine!

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more

About GNH

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more
  • No data
  • To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZOSYN and other antibacterial drugs, ZOSYN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
  • ZOSYN is a combination product consisting of a penicillin-class antibacterial, piperacillin, and a u03b2-lactamase inhibitor, tazobactam, indicated for the treatment of patients with moderate to severe infections caused by susceptible isolates of the designated bacteria in the conditions listed below.
  • ZOSYN is a combination penicillin-class antibacterial and u03b2-lactamase inhibitor indicated for treatment of:
  • To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZOSYN and other antibacterial drugs, ZOSYN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.()
  • Intra-abdominal infections ()
  • Skin and skin structure infections ()
  • Female pelvic infections ()
  • Community-acquired pneumonia ()
  • Nosocomial pneumonia ()
  • Usage ()
  • ZOSYN should be administered by intravenous infusion over 30 minutes.
  • The usual daily dose of ZOSYN for adults is 3.375 g every six hours totaling 13.5 g (12.0 g piperacillin/1.5 g tazobactam). ()
  • Initial presumptive treatment of patients with nosocomial pneumonia should start with ZOSYN at a dosage of 4.5 g every six hours plus an aminoglycoside, totaling 18.0 g (16.0 g piperacillin/2.0 g tazobactam). ()
  • Dosage in patients with renal impairment (u226440 mL/min of CRCL) and dialysis patients should be reduced, based on the degree of actual renal function impairment. ()
  • For children with appendicitis and/or peritonitis the recommended ZOSYN dosage is 100 mg piperacillin/12.5 mg tazobactam per kilogram of body weight, every 8 hours in pediatric patients 9 months of age and older. For pediatric patients 2 to 9 months of age, the recommended dosage is 80 mg piperacillin/10 mg tazobactam per kilogram of body weight, every 8 hours.()
  • ZOSYN and aminoglycosides should be reconstituted, diluted, and administered separately. Co-administration via Y-site can be done under certain conditions. ()
  • ZOSYN (piperacillin and tazobactam) for Injection is supplied as a white to off-white powder in vials of the following sizes:
  • Each ZOSYN 2.25 g vial provides piperacillin sodium equivalent to 2 grams of piperacillin and tazobactam sodium equivalent to 0.25 g of tazobactam.
  • Each ZOSYN 3.375 g vial provides piperacillin sodium equivalent to 3 grams of piperacillin and tazobactam sodium equivalent to 0.375 g of tazobactam.
  • Each ZOSYN 4.5 g vial provides piperacillin sodium equivalent to 4 grams of piperacillin and tazobactam sodium equivalent to 0.5 g of tazobactam.
  • Each ZOSYN 40.5 g pharmacy bulk vial contains piperacillin sodium equivalent to 36 grams of piperacillin and tazobactam sodium equivalent to 4.5 grams tazobactam.
  • ZOSYN (piperacillin and tazobactam) Injection is supplied in GALAXY Containers as a frozen, iso-osmotic, sterile, non-pyrogenic solution in single-dose plastic containers:
  • 2.25 g (piperacillin sodium equivalent to 2 g piperacillin/tazobactam sodium equivalent to 0.25 g tazobactam) in 50 mL.
  • 3.375 g (piperacillin sodium equivalent to 3 g piperacillin/tazobactam sodium equivalent to 0.375 g tazobactam) in 50 mL.
  • 4.5 g (piperacillin sodium equivalent to 4 g piperacillin/tazobactam sodium equivalent to 0.5 g tazobactam) in 100 mL.
  • ZOSYN for Injection: 2.25 g, 3.375 g, and 4.5 g lyophilized powder for reconstitution in single-dose vials and 40.5 g lyophilized powder for reconstitution in pharmacy bulk vials. ()
  • ZOSYNInjection: 2.25 g in 50 mL, 3.375 g in 50 mL, and 4.5 g in 100 mL frozen solution in single-dose GALAXY containers.(, )
  • ZOSYN is contraindicated in patients with a history of allergic reactions to any of the penicillins, cephalosporins, or u03b2-lactamase inhibitors.
  • Patients with a history of allergic reactions to any of the penicillins, cephalosporins, or u03b2-lactamase inhibitors. ()
  • No data
  • Serious hypersensitivity reactions (anaphylactic/anaphylactoid) reactionshave been reported in patients receiving ZOSYN. Discontinue ZOSYN if a reaction occurs. ()
  • ZOSYN may cause severe cutaneous adverse reactions, such as Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, and acute generalized exanthematous pustulosis (). Discontinue ZOSYN for progressive rashes.
  • Hematological effects (including bleeding, leukopenia and neutropenia) have occurred. Monitor hematologic tests during prolonged therapy. ()
  • Nephrotoxicity in critically ill patients has been observed; the use of ZOSYN was found to be an independent risk factor for renal failure and was associated with delayed recovery of renal function as compared to other beta-lactam antibacterial drugs in a randomized, multicenter, controlled trial in critically ill patients. Based on this study, alternative treatment options should be considered in the critically ill population. If alternative treatment options are inadequate or unavailable, monitor renal function during treatment with ZOSYN. ()
  • Clostridium difficile
  • The most common adverse reactions (incidence >5%) are diarrhea, constipation, nausea, headache and insomnia. ()
  • To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
  • No data
  • ZOSYN administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. ()
  • Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with ZOSYN unless the benefit outweighs the risk. ()
  • Co-administration of ZOSYN with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving ZOSYN and vancomycin. ()
  • Monitor coagulation parameters in patients receiving ZOSYN and heparin or oral anticoagulants. ()
  • ZOSYN may prolong the neuromuscular blockade of vecuronium and other non-depolarizing muscle relaxants. Monitor for adverse reactions related to neuromuscular blockade ()
  • Dosage in patients with renal impairment (u226440 mL/min of CRCL) should be reduced to the degree of actual renal function impairment. (, )
  • There have been postmarketing reports of overdose with piperacillin/tazobactam. The majority of those events experienced, including nausea, vomiting, and diarrhea, have also been reported with the usual recommended dosages. Patients may experience neuromuscular excitability or convulsions if higher than recommended doses are given intravenously (particularly in the presence of renal failure) [].
  • Treatment should be supportive and symptomatic according the patient's clinical presentation. Excessive serum concentrations of either piperacillin or tazobactam may be reduced by hemodialysis. Following a single 3.375 g dose of piperacillin/tazobactam, the percentage of the piperacillin and tazobactam dose removed by hemodialysis was approximately 31% and 39%, respectively [].
  • ZOSYN (piperacillin and tazobactam) for Injection and ZOSYN (piperacillin and tazobactam) Injection are injectable antibacterial combination products consisting of the semisynthetic antibacterial piperacillin sodium and the u03b2-lactamase inhibitor tazobactam sodium for intravenous administration.
  • Piperacillin sodium is derived from D(-)-u03b1-aminobenzyl-penicillin. The chemical name of piperacillin sodium is sodium (2,5,6)-6-[()-2-(4-ethyl-2,3-dioxo-1-piperazine-carboxamido)-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate. The chemical formula is CHNNaOS and the molecular weight is 539.5. The chemical structure of piperacillin sodium is:
  • Tazobactam sodium, a derivative of the penicillin nucleus, is a penicillanic acid sulfone. Its chemical name is sodium (235)-3-methyl-7-oxo-3-(1-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate-4,4-dioxide. The chemical formula is CHNNaOS and the molecular weight is 322.3. The chemical structure of tazobactam sodium is:
  • ZOSYN (piperacillin and tazobactam) for Injection, is a white to off-white sterile, cryodesiccated powder consisting of piperacillin and tazobactam as their sodium salts packaged in glass vials. The formulation also contains edetate disodium dihydrate (EDTA) and sodium citrate.
  • Each ZOSYN 2.25 g single dose vial contains an amount of drug sufficient for withdrawal of piperacillin sodium equivalent to 2 grams of piperacillin and tazobactam sodium equivalent to 0.25 g of tazobactam. The product also contains 0.5 mg of EDTA per vial.
  • Each ZOSYN 3.375 g single dose vial contains an amount of drug sufficient for withdrawal of piperacillin sodium equivalent to 3 grams of piperacillin and tazobactam sodium equivalent to 0.375 g of tazobactam. The product also contains 0.75 mg of EDTA per vial.
  • Each ZOSYN 4.5 g single dose vial contains an amount of drug sufficient for withdrawal of piperacillin sodium equivalent to 4 grams of piperacillin and tazobactam sodium equivalent to 0.5 g of tazobactam. The product also contains 1 mg of EDTA per vial.
  • Each Zosyn 40.5 g pharmacy bulk vial contains piperacillin sodium equivalent to 36 grams of piperacillin and tazobactam sodium equivalent to 4.5 g of tazobactam sufficient for delivery of multiple doses.
  • ZOSYN Injection in the GALAXY Container is a frozen iso-osmotic sterile non-pyrogenic premixed solution. The components and dosage formulations are given in the table below:
  • ZOSYN contains a total of 2.84 mEq (65 mg) of sodium (Na) per gram of piperacillin in the combination product.
  • No data
  • Long-term carcinogenicity studies in animals have not been conducted with piperacillin/tazobactam, piperacillin, or tazobactam.
  • CLINITEST is a registered trademark of Siemens Healthcare Diagnostics Inc.
  • GALAXY is a registered trademark of Baxter International Inc.
  • ZOSYN (piperacillin and tazobactam) for Injection are supplied as single-dose vials and pharmacy bulk vials in the following sizes:
  • ZOSYN for Injection vials should be stored at controlled room temperature (20u00b0C to 25u00b0C [68u00b0F to 77u00b0F]) prior to reconstitution.
  • ZOSYN (piperacillin and tazobactam) Injection in GALAXY Containers are supplied as a frozen, iso-osmotic, sterile, nonpyrogenic solution in single dose plastic containers as follows:
  • ZOSYN Injection in GALAXY Containers should be stored at or below -20u00b0C (-4u00b0F).
  • No data
  • LAB-0690-10.0t
  • NDC 0206-8852-08
  • 2.25 gram Single Use Vial
  • Zosynn
  • (piperacillin and tazobactam) for injection
  • 2.25 gram
  • For IV Use Only
  • Rx only
  • NDC 0206-8852-16Contains 10 vials ofNDC 0206-8852-08n n
  • 10 x 2.25 gram Single Use Vials
  • Zosynn
  • 2.25 gram
  • For IV Use Only
  • Pfizer Injectables
  • ZOSYNn (Piperacillin and TazobactamInjection)
  • 2.25 g
  • Rx only
  • GALAXY
  • Single DoseContainer
  • 50 mLIso-osmotic
  • NDC 0206-8860-01Code 2G3575Sterile Nonpyrogenic
  • Store at or below -20u00b0C/-4u00b0F. Thaw at room temperature 20u00b0 to 25u00b0C (68u00b0 to 77u00b0F)or under refrigeration 2u00b0 to 8u00b0C (36u00b0 to 46u00b0F). DO NOT FORCE THAW BY IMMERSIONIN WATER BATHS OR BY MICROWAVE IRRADIATION. Thawed solution remainsstable for 14 days under refrigeration or 24 hours at room temperature.
  • Do not refreeze.
  • Dosage and Use: For intravenous use only. As directed by a physician. See Package Insert.Cautions: Do not add supplementary medication or additives. Must not be usedin series connections. Check for minute leaks and solution clarity.
  • Each 50 mL contains: Piperacillin Sodium equivalent to 2 g Piperacillin andTazobactam Sodium equivalent to 0.25 g Tazobactam in Water for Injection.
  • Approximately 1 g Dextrose Hydrous added to adjust osmolality. Approximately100 mg Sodium Citrate Dihydrate added as a buffer. pH adjusted with sodiumbicarbonate and hydrochloric acid. pH 5.5 - 6.8
  • Each 50 mL also contains approximately 0.5 mg Edetate Disodium Dihydrate addedas a metal chelator.
  • GALAXY is a registered trademark of Baxter International Inc.
  • Distributed byWyeth Pharmaceuticals LLCA subsidiary of Pfizer IncPhiladelphia, PA 19101
  • PL 2040 Plastic
  • 1460520007-34-00-0150
  • Pfizer Injectables
  • ZOSYNn (Piperacillin and Tazobactam Injection)
  • Rx only
  • 2.25 g
  • 2 x 12 x 50 mL Single Dose ContainersContains 2 boxes of 12 of NDC 0206-8860-01Iso-osmoticStore at orbelow -20u00b0C/-4u00b0F.Do not refreeze.
  • NDC 0206-8860-02Contains 24 of NDC 0206-8860-01tttttttCode 2G3575
  • Pfizer Injectables
  • NDC 0206-8854-08
  • 3.375 gram Single Use Vial
  • Zosynn
  • (piperacillin and tazobactam) for injection
  • 3.375 gram
  • For IV Use Only
  • Rx only
  • NDC 0206-8854-16Contains 10 vials ofNDC 0206-8854-08n n
  • 10 x 3.375 gram Single Use Vials
  • Zosynn
  • 3.375 gram
  • For IV Use Only
  • Pfizer Injectables
  • ZOSYNn (Piperacillin and TazobactamInjection)
  • 3.375 g
  • Rx only
  • GALAXY
  • Single DoseContainer
  • 50 mLIso-osmotic
  • NDC 0206-8861-01Code 2G3576Sterile Nonpyrogenic
  • Store at or below -20u00b0C/-4u00b0F. Thaw at room temperature 20u00b0 to 25u00b0C (68u00b0 to 77u00b0F)or under refrigeration 2u00b0 to 8u00b0C (36u00b0 to 46u00b0F). DO NOT FORCE THAW BY IMMERSIONIN WATER BATHS OR BY MICROWAVE IRRADIATION. Thawed solution remainsstable for 14 days under refrigeration or 24 hours at room temperature.
  • Do not refreeze.
  • Dosage and Use: For intravenous use only. As directed by a physician. See Package Insert.Cautions: Do not add supplementary medication or additives. Must not be usedin series connections. Check for minute leaks and solution clarity.
  • Each 50 mL contains: Piperacillin Sodium equivalent to 3 g Piperacillin andTazobactam Sodium equivalent to 0.375 g Tazobactam in Water for Injection.
  • Approximately 350 mg Dextrose Hydrous added to adjust osmolality. Approximately150 mg Sodium Citrate Dihydrate added as a buffer. pH adjusted with sodiumbicarbonate and hydrochloric acid. pH 5.5 - 6.8
  • Each 50 mL also contains approximately 0.75 mg Edetate Disodium Dihydrate addedas a metal chelator.
  • GALAXY is a registered trademark of Baxter International Inc.
  • Distributed byWyeth Pharmaceuticals LLCA subsidiary of Pfizer IncPhiladelphia, PA 19101
  • PL 2040 Plastic
  • 1460490007-34-00-0151
  • Pfizer Injectables
  • ZOSYNn (Piperacillin and Tazobactam Injection) tttttt
  • Rx only
  • 3.375g
  • 2 x 12 x 50 mL Single Dose ContainersContains 2 boxes of 12 of NDC 0206-8861-01Iso-osmoticStore at orbelow -20u00b0C/-4u00b0F.Do not refreeze.
  • NDC 0206-8861-02Contains 24 of NDC 0206-8861-01tttttttCode 2G3576
  • Pfizer Injectables
  • NDC 0206-8855-08
  • 4.5 gram Single Use Vial
  • Zosynn
  • (piperacillin and tazobactam) for injection
  • 4.5 gram
  • For IV Use Only
  • Rx only
  • NDC 0206-8855-16Contains 10 ofNDC 0206-8855-08n n
  • 10 x 4.5 gram Single Use Vials
  • Zosynn
  • 4.5 gram
  • For IV Use Only
  • Pfizer Injectables
  • ZOSYNn (Piperacillin and TazobactamInjection)
  • 4.5 g
  • Rx only
  • GALAXY
  • Single DoseContainer
  • 100 mLIso-osmotic
  • NDC 0206-8862-01Code 2G3577Sterile Nonpyrogenic
  • Store at or below -20u00b0C/-4u00b0F. Thaw at room temperature 20u00b0 to 25u00b0C (68u00b0 to 77u00b0F)or under refrigeration 2u00b0 to 8u00b0C (36u00b0 to 46u00b0F). DO NOT FORCE THAW BY IMMERSIONIN WATER BATHS OR BY MICROWAVE IRRADIATION. Thawed solution remainsstable for 14 days under refrigeration or 24 hours at room temperature.
  • Do not refreeze.
  • Dosage and Use: For intravenous use only. As directed by a physician. See Package Insert.Cautions: Do not add supplementary medication or additives. Must not be usedin series connections. Check for minute leaks and solution clarity.
  • Each 100 mL contains: Piperacillin Sodium equivalent to 4 g Piperacillin andTazobactam Sodium equivalent to 0.5 g Tazobactam in Water for Injection.
  • Approximately 2 g Dextrose Hydrous added to adjust osmolality. Approximately200 mg Sodium Citrate Dihydrate added as a buffer. pH adjusted with sodiumbicarbonate and hydrochloric acid. pH 5.5 - 6.8
  • Each 100 mL also contains approximately 1 mg Edetate Disodium Dihydrate addedas a metal chelator.
  • GALAXY is a registered trademark of Baxter International Inc.
  • Distributed byWyeth Pharmaceuticals LLCA subsidiary of Pfizer IncPhiladelphia, PA 19101
  • PL 2040 Plastic
  • 1460510007-34-00-0152
  • Pfizer Injectables
  • ZOSYNn (Piperacillin and Tazobactam Injection)
  • Rx only
  • 4.5 g
  • 2 x 6 x 100 mL Single Dose ContainersContains 2 boxes of 6 of NDC 0206-8862-01Iso-osmoticStore at orbelow -20u00b0C/-4u00b0F.Do not refreeze.
  • NDC 0206-8862-02Contains 12 of NDC 0206-8862-01tttttttCode 2G3577
  • Pfizer Injectables
  • PRINCIPAL DISPLAY PANEL- 40.5 gram Vial Label
  • Pfizer Injectables
  • NDC 0206-8859-10
  • Zosynn Rx only
  • (Piperacillin and Tazobactamfor Injection, USP)
  • 40.5 gram vial
  • PHARMACY BULK PACKAGENot for Direct Infusion
  • Distributed by Wyeth Pharmaceuticals IncA subsidiary of Pfizer Inc, Philadelphia, PA 19101
  • PRINCIPAL DISPLAY PANEL - 40.5 gram Vial Carton
  • NDC 0206-8859-10n n
  • Zosynn
  • (Piperacillin and Tazobactamfor Injection, USP)
  • 40.5 gram vial
  • PHARMACY BULK PACKAGENot for Direct Infusion
  • RECONSTITUTED STOCK SOLUTION MUST BETRANSFERRED AND FURTHER DILUTEDFOR I.V. INFUSION
  • Pfizer Injectables

Similar Products

Desogestrel And Ethinyl Estradiol (Emoquette)

Desogestrel And Ethinyl Estradiol (Emoquette)

Manufacturer: REMEDYREPACK INC.

Presentation: KIT

Strength:

Pack Size:

Diphenoxylate Hydrochloride And Atropine Sulfate (Diphenoxylate Hydrochloride And Atropine Sulfate)

Diphenoxylate Hydrochloride And Atropine Sulfate (Diphenoxylate Hydrochloride And Atropine Sulfate)

Manufacturer: REMEDYREPACK INC.

Presentation: TABLET

Strength: 2.5; .025 mg/1; mg/1

Pack Size:

Fluoxetine Hydrochloride (Fluoxetine)

Fluoxetine Hydrochloride (Fluoxetine)

Manufacturer: REMEDYREPACK INC.

Presentation: CAPSULE

Strength: 40 mg/1

Pack Size:

Metoprolol Succinate (Metoprolol Succinate)

Metoprolol Succinate (Metoprolol Succinate)

Manufacturer: REMEDYREPACK INC.

Presentation: TABLET, EXTENDED RELEASE

Strength: 25 mg/1

Pack Size:

Losartan Potassium (Losartan Potassium)

Losartan Potassium (Losartan Potassium)

Manufacturer: REMEDYREPACK INC.

Presentation: TABLET, FILM COATED

Strength: 25 mg/1

Pack Size:

Browse Our Services And Processes

Comparator Sourcing for Clinical Trials

Comparator Sourcing for Clinical Trials

GNH India brings over 10 years of experience in Comparator

Read More

Name Patient Supply

Name Patient Supply

Today, the exact cause for many rare diseases remains unknown

Read More

Validated Cold Chain Shipment

Validated Cold Chain Shipment

With shifting of pharma industry from synthetic molecules to biologic

Read More

Clinical Trials Supply

Clinical Trials Supply

STOP SOURCING..... START SMART SOURCING...... COME STRAIGHT TO THE SOURCE

Read More

Pharmaceutical Contract Manufacturing

Pharmaceutical Contract Manufacturing

GNH Provides Contract Manufacturing services for: Generic Medicines with following

Read More

Pricing

Pricing

PRICING POLICY Terms of sales are typically prepaid, unless otherwise

Read More

Disclaimer

Please see the Legal Notice for detailed terms and disclaimers. The Legal Notice governs the use of this Website and by accessing and using this Website you agree to be bound by and accept the Legal Notice.

Browse from other international pharmaceuticals

General

64020 Products

GNH India Brings to over 64036 Product SKUs from India all at 1 place with easy access and global deliveries.

US NDC

71246 Products

GNH India Brings to over 71252 Product SKUs from India all at 1 place with easy access and global deliveries.

Canadian DIN

51046 Products

GNH India Brings to over 51047 Product SKUs from India all at 1 place with easy access and global deliveries.

Swiss Drugs

150 Products

GNH India Brings to over 150 Product SKUs from India all at 1 place with easy access and global deliveries.

NZ Drugs

13296 Products

GNH Brings to over 13298 Product SKUs from India all at 1 place with easy access and global deliveries.

FAQ

Check out our delivery process

Can’t find what
you’re looking for?

Contact US
Get Price

Are you an existing customer or a vendor of GNH India? Log in here to

View your Transaction
COMPANY
SERVICES
QUICK LINKS
CONTACT US
Registered Office Address:

Unit # G- 14, 15, 16, 17, Ground Floor, Prabhadevi Industrial Estate, Enterprises Industrial Premises, 408, Veer Sawarkar Road, Prabhadevi,
Mumbai 400025 India

US Office Address:

GNH Pharmaceuticals USA LLC,
Suite E # 499, 1235 EAST BLVD,
Charlotte, NC, 28203, U.S.A
TEL: +1 704 557 0412

Pharmexcil
DB
FIEO-2016
SiteLock

Copyright © 2024 GNHIndia .com. All Rights Reserved. Please read Legal Notice for further details.

Disclaimer: Product names, logos, brands and other trademarks featured or referred to are the property of their respective trademark holders.